The first molecules to target this site were inhibitors of KRAS G12C mutant that is most prevalent in non-small cell lung cancer and lung adenocarcinomas [29], in which presence of KRAS mutations mean worse prognosis, and elevated resistance for certain therapies [30–32]. This evidence concerns the gene KRAS and lung adenocarcinoma.